Moomoo AIのまとめ
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
2024年3月27日、Avalo Therapeutics社は重要なイベントを経験しました。Emerald Bioventures、LLCとそのマネージングメンバーであるTimothy Oplerが、SECにSchedule 13Gを提出し、Avalo Therapeuticsの普通株式の5.6％の所有権を示しました。この申請は、合併によりEmerald Bioventures、LLCがAvalo Therapeuticsの普通株式58,346株を取得した結果、必要とされました。合併は、Avalo Therapeutics、Project Athens Merger Sub、Inc.、Seco...すべて展開
2024年3月27日、Avalo Therapeutics社は重要なイベントを経験しました。Emerald Bioventures、LLCとそのマネージングメンバーであるTimothy Oplerが、SECにSchedule 13Gを提出し、Avalo Therapeuticsの普通株式の5.6％の所有権を示しました。この申請は、合併によりEmerald Bioventures、LLCがAvalo Therapeuticsの普通株式58,346株を取得した結果、必要とされました。合併は、Avalo Therapeutics、Project Athens Merger Sub、Inc.、Second Project Athens Merger Sub、LLC、およびAlmataBio、Inc.が関与し、後者の2つのエンティティはAvalo Therapeuticsの完全子会社に合併しました。この株式は、合併当日に取得され、所有比率は、その日時点での1,034,130株の普通株式を基に算出されます。Rule 13d-1(c)に基づいて行われたSchedule 13Gの申請によると、Emerald Bioventures、LLCもTimothy Oplerも、株式に対する単独の投票権または意思決定権を持っていませんが、投票権および意思決定権を共有することを示しています。この申請は、株式がAvalo Therapeuticsの統制を変更または影響する目的で取得されたものではないと主張しています。
役に立った
役に立たない